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Abstract
Background: This study evaluated two doses of etoricoxib (60 and 90 mg) vs. naproxen 1000 mg in subjects with
ankylosing spondylitis (AS).
Methods: This was a 2-part, double-blind, active comparator-controlled non-inferiority study in subjects ≥18 years
of age with AS. In Part I, subjects were randomized to naproxen 1000 mg; etoricoxib 60 mg, and 90 mg. In Part II,
naproxen and etoricoxib 90 mg subjects continued on the same treatment; subjects on etoricoxib 60 mg either
continued on 60 mg or escalated to 90 mg. Part I (6 weeks) assessed the efficacy of A) etoricoxib 60 mg vs.
naproxen and B) 90 mg vs. naproxen according to the time-weighted average change from baseline in Spinal Pain
Intensity (SPI; 0–100 mm VAS) (primary endpoint). The non-inferiority margin was set at 8 mm for SPI. In Part II
(20 weeks) we evaluated the potential benefit of increasing from 60 to 90 mg (predefined minimum clinically
important difference = 6 mm in SPI) for inadequate responders (<50 % improvement from baseline in SPI) on
etoricoxib 60 mg in Part I.
Results: In total, 1015 subjects were randomized to receive etoricoxib 60 mg (N = 702), etoricoxib 90 mg (N = 156),
and naproxen 1000 mg (N = 157); 70.9 % were male and the mean age was 45.2 years. There were 919 subjects
who completed Part I and all continued to Part II. In Part I, SPI change was non-inferior for both etoricoxib doses vs.
naproxen. In both Part I and II, the incidence of adverse events (AEs), drug-related AEs, and serious adverse events
(SAEs) were similar between the 3 treatment groups.
Conclusion: Both doses of etoricoxib were non-inferior to naproxen. All treatments were well tolerated. Etoricoxib
60 and 90 mg effectively control pain in patients with AS, with 60 mg once daily as the lowest effective dose for
most patients.
Trial registration: Clinical Trials Registry # NCT01208207. Registered on 22 September 2010.
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Background
Ankylosing spondylitis (AS) is a chronic inflammatory
spinal disorder in which patients most frequently report
spinal pain, with pain at night and pain upon awakening
being major features [1]. The chronic pain experienced
by patients with AS often leads to interference in daily
life and reduces the ability of patients to work and en-
gage in social activities, thus impacting psychological
well-being in addition to their physical disability [2].
Pain in AS has been associated with fatigue, which can
also affect quality of life [3].
Non-steroidal anti-inflammatory drugs (NSAIDs) are
treatments that have been used to treat pain and inflamma-
tion for several decades. In AS, they are recommended as
first-line therapies by the ASsessment in AS international
working group, the European League Against Rheumatism
(ASAS/EULAR), and by the American College of Rheuma-
tology (ACR) [4–6]. More recently, biologic therapies have
become more widely adopted as treatments for AS and are
associated with significant improvements of inflammatory
burden and functional ability. However, NSAIDs have also
demonstrated important treatment effects for AS patients.
A recent systematic review suggests that there is high qual-
ity evidence from multiple randomized controlled trials
suggesting that NSAIDs and COX-2 selective inhibitors are
effective in managing spinal pain, peripheral joint pain and
improving function [7]. In addition, NSAIDs have been
shown to have additional therapeutic benefit in AS patients.
NSAIDs inhibit prostaglandin synthesis through inhibition
of the enzyme cyclooxygenase (COX). Prostaglandin E2
(PGE2) promotes osteoclast activity and stimulates osteo-
blast activity and in AS patients, this can potentially cause
new pathologic bone formation. Previous studies have dem-
onstrated that NSAIDs can slow radiographic progression
in AS patients and may be more pronounced with COX-2
selective NSAIDs, although such findings could not be con-
firmed in all studies [8–10].
Etoricoxib, a COX-2 selective NSAID has demon-
strated therapeutic benefit in patients with AS, as well as
other acute and chronic pain conditions [11–16]. Results
of a 52-week study in AS patients demonstrated that
etoricoxib 90 mg and 120 mg were superior to placebo
over 6-weeks and were superior to naproxen 500 mg
BID (twice daily) over 1 year of treatment [16]. The effi-
cacy of etoricoxib 90 and 120 mg did not differ, and
thus, etoricoxib 90 mg was determined to be the most
appropriate dose for AS patients.
This study was designed to further assess the dose-
related efficacy and safety/tolerability profile of etori-
coxib in subjects with AS by comparing etoricoxib
60 mg with naproxen 1000 and 90 mg with naproxen
1000 mg over 6 weeks and evaluating the potential bene-
fit of increasing the etoricoxib dose to 90 mg in those
subjects with inadequate pain responses to 60 mg.
Methods
This study (Clinical Trials Registry # NCT01208207, Spon-
sor Protocol MK-0663 Protocol 108) was conducted at 187
study centers in Argentina, Austria, Belgium, Canada,
Columbia, Czech Republic, Estonia, Finland, France,
Germany, Hungary, India, Lithuania, Mexico, Poland,
Romania, Russia, Slovakia, South Africa, Taiwan, the United
Kingdom, and the United States. The study was initiated in
September 2010 and completed in November 2014. The
protocol for the study was approved by local institutional
review boards or ethical review committees and was con-
ducted according to principles of Good Clinical Practice.
Subjects provided informed consent prior to participation
in the study.
Subjects
Subjects who were included were male or female, at least
18 years of age, and had a diagnosis of AS by the Modified
New York criteria (determined/assessed at Visit 1) [17].
Subjects were to have had a history of positive therapeutic
benefit with NSAIDs and were to have taken an NSAID
on a regular basis and at a therapeutic dose level for at
least 30 days prior to study enrollment. If subjects were
using anti-rheumatic therapies other than NSAIDs, these
were to be held at stable doses throughout the study
duration. Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI) questionnaires were completed at each
treatment visit and consisted of 6 questions pertaining to
fatigue, spinal pain, joint pain/swelling, areas of localized
tenderness, morning stiffness duration and morning stiff-
ness severity. Subjects were required to have a baseline
score on BASDAI Question 2 (Spinal Pain Intensity [SPI];
0–100 mm on a visual analog scale [VAS]) at Visit 1 that
was <77 mm. After “washout” of prestudy NSAID, sub-
jects had to satisfy flare criteria before randomization.
This flare criteria (i.e., worsening of spinal pain) was de-
fined as a score on SPI after withdrawal of baseline
NSAIDs that was: ≥40 mm, AND ≥30 % higher than the
SPI score prior to NSAID withdrawal, AND ≥12 mm
higher than the SPI prior to NSAID withdrawal.
Subjects were excluded from the study if they had
conditions that would confound study results includ-
ing a history of gastrointestinal (GI) surgery that
causes clinical malabsorption, neoplastic disease, or a
bleeding disorder (inherited or acquired). Additional
conditions leading to exclusion were active peptic
(gastric or duodenal) ulcer or history of inflammatory
bowel disease, ischemic heart disease, cerebrovascular
disease, or peripheral artery occlusive disease, class II-
IV congestive heart failure, uncontrolled hypertension
at Visit 1 or 2, BMI ≥40 kg/m2 and significant health
problems stemming from obesity, estimated glomeru-
lar filtration rate ≤30 mL/min, or hepatic insufficiency
(Child-Pugh score ≥5).
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Study design
This was a 2-part, double-blind, active-comparator-
controlled study in subjects with AS. Part I was a 6-week,
active-comparator-controlled period to compare the effi-
cacy of etoricoxib 90 mg to naproxen1000 mg, the efficacy
of etoricoxib 60 mg to naproxen 1000 mg and the efficacy
of the 60 and 90 mg doses to each other. Part II was a 20-
week, long-term treatment period that evaluated subjects
who remained on naproxen 1000 mg, etoricoxib 90 mg,
and etoricoxib 60 mg as well as subjects who escalated
from etoricoxib 60 to 90 mg. Subjects were randomized at
baseline (Visit 2) to one of four treatment sequences (treat-
ment in Part I/treatment in Part II) in a 4:9:9:4 ratio: 1) na-
proxen 1000 mg/naproxen 1000 mg; 2) Etoricoxib 60 mg/
etoricoxib 60 mg; 3) Etoricoxib 60 mg/etoricoxib 90 mg; 4)
Etoricoxib 90 mg/etoricoxib 90 mg. Randomization was
stratified by the presence or absence of chronic peripheral
arthritis. Subjects were evaluated at Weeks 2, 4 and 6 in
Part I. Subjects were evaluated at Weeks 10, 12, 18, and 26
in Part II.
Safety was monitored from screening throughout the
study, and up to 28 days after the last dose of study
medication.
Efficacy parameters
The primary endpoint in this study was the time-
weighted average change from baseline in SPI (100-mm
VAS) over 6 weeks. The primary hypotheses were that
etoricoxib 90 mg once daily is not inferior to naproxen
1000 mg according to the primary endpoint and that
etoricoxib 60 mg once daily is not inferior to naproxen
1000 mg according to the primary endpoint. The Per
Protocol Population (excludes subjects with important
protocol deviations) was used for the analysis of the
Primary Endpoint. Key Secondary Endpoints included
time-weighted average change from baseline in SPI
(VAS) in Part I (etoricoxib 90 mg vs. etoricoxib 60 mg;
using the Modified Intention to Treat population
[mITT]) and average change from Week 6 in SPI (VAS)
over the average of Weeks 10 and 12 among inadequate
responders to etoricoxib 60 mg (inadequate responder
defined as a subject with <50 % improvement from
baseline in SPI [VAS] at Week 6). Other Secondary
Endpoints included time-weighted average change from
baseline in SPI (VAS) over 26 weeks, time-weighted
average response in Patient Global Assessment of
Response to Therapy (PGART; Likert) over 6 weeks,
proportion of subjects who discontinue due to lack of
efficacy over 6 weeks, average change from Week 6 in
PGART (Likert) over Weeks 10 and 12, and change
from baseline in SPI (VAS) at each week of the study.
We also evaluated the BASDAI composite score (VAS)
and the morning stiffness duration and severity.
Safety parameters
Safety assessments included physical examinations, vital
signs, limited hematology and chemistry (i.e., hemoglobin,
hematocrit, alanine aminotransferase [ALT], aspartate
transaminase [AST], creatinine, and serum digoxin for sub-
jects on digoxin), hematology [hemoglobin and hematocrit],
urinalysis, serum or urine pregnancy testing, and serum
FSH. Spontaneous adverse experience (AE) were monitored
and reported up to 28 days (+2 days) after the last dose of
study medication. All thrombotic CV SAEs and upper GI
events (such as perforation, ulcer, or upper GI bleeding)
that occurred in subjects in this study were subject to adju-
dication by a committee external to the Sponsor during the
study.
Statistical planning and analysis
The primary population analyzed for the primary hypoth-
esis was the per-protocol population. The mITT popula-
tion (randomized subjects who received at least 1 dose of
study medication, had at least 1 post-randomization meas-
urement for the analysis endpoint, and had baseline data)
was used for a supportive analysis of the primary efficacy
analyses and was the primary analysis population for all
the secondary objectives. For evaluation of the primary ob-
jectives, the sample sizes in this study provided 91 % power
(α = 0.025, 1-sided) for etoricoxib 90 mg vs. naproxen,
>99 % (α =0.025, 1-sided) for etoricoxib 60 mg vs. na-
proxen. For secondary objectives, this study had 91 %
power (α =0.20, 2-sided), and 80 % power (α =0.20, 2-
sided) for etoricoxib 60 mg/90 mg vs. etoricoxib 60 mg/
60 mg in inadequate responders.
The primary endpoint was analyzed using an analysis of
covariance (ANCOVA). For the comparison of etoricoxib
90 mg vs. naproxen and the comparison of etoricoxib
60 mg vs. naproxen, non-inferiority was established if the
upper bound of the 2-sided 95 % confidence interval of
the between-treatment difference in the Least Square (LS)
means (etoricoxib minus naproxen 1000 mg) was no lar-
ger than 8 mm VAS (non-inferiority margin based on a
previous etoricoxib study in ankylosing spondylitis [16]).
Etoricoxib 90 mg was declared superior to etoricoxib
60 mg if the difference in LS means for the primary end-
point was significant (p ≤ 0.20) in favor of the 90-mg dose.
A difference of 6 mm VAS in the time-weighted average
change from baseline over 6 weeks between two doses on
SPI (VAS) is considered to be a Minimum Clinically
Important Difference (MCID; i.e., a clinically important
difference in means). This value was assigned after taking
into account advice from consulted experts and data from
dose range-finding studies since no specific literature was
identified to aid in the assignment of MCID between
doses in an AS population.
The comparison of inadequate responders in Part II was
analyzed using ANCOVA. A difference of 6 mm VAS, as
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measured by the average change from Week 6 to Weeks
10 and 12 in SPI, was also assigned as a MCID for the
comparison of etoricoxib 60 mg/etoricoxib 90 mg and
etoricoxib 60 mg/etoricoxib 60 mg treatment sequences.
The benefit of a dose increase from 60 to 90 mg was indi-
cated if the nominal p-value (without multiplicity adjust-
ment) for difference in LS means between the 2 treatment
sequences was ≤0.20 in favor of the 90-mg dose.
The All Patients as Treated (APaT) population was
used for the analysis of safety data (i.e., all randomized
subjects who received at least 1 dose of study treatment).
For pre-specified AEs of interest, p-values and/or 95 %
CI’s were provided using the Miettinen and Nurminen
method for treatment group comparisons. All other AEs
were summarized with counts and percentages.
Results
Subjects
There were 1015 subjects randomized to etoricoxib
60 mg (n = 702), etoricoxib 90 mg (n = 156), and na-
proxen 1000 mg (n = 157) in Part I. Of these randomized
subjects, 919 subjects completed Part I (91 %). The most
common reasons for early discontinuation were adverse
events and lack of efficacy. Rates of discontinuation were
low and similar across all treatment groups (Fig. 1). Of
the 919 subjects entering Part II, 314 subjects continued
receiving etoricoxib 60 mg, 145 subjects continued re-
ceiving etoricoxib 90 mg, 142 subjects continued receiv-
ing naproxen 1000 mg, and 318 subjects switched from
etoricoxib 60 mg to etoricoxib 90 mg. There were 837
subjects who completed Part II (91 %), with similar dis-
tributions in the reasons for discontinuation between
the treatment groups (Fig. 1). Baseline demographics
were similar among the treatment groups; the majority
of randomized subjects were male (70.9 %), subject ages
varied from 19 to 82 years at enrollment, and the mean
subject age at enrollment was 45.2 years. With regard to
baseline disease characteristics in Part I, 302 (29.8 %)
subjects had chronic peripheral arthritis, 244 (24.0 %)
subjects had grade 4 bilateral sacroiliitis radiographic as-
sessment according to the modified NY criteria. There
were no clinically meaningful differences between the
treatment groups for these or any other baseline disease-
related characteristics (Table 1).
Efficacy
For the primary endpoint of the time-weighted average
change from baseline SPI score over 6 weeks of treat-
ment in Part I, results were similar between the etori-
coxib 60 mg, etoricoxib 90 mg, and naproxen 1000 mg
groups (Figs. 2 and 3). For the comparisons of etoricoxib
60 mg vs. naproxen and 90 mg vs. naproxen, the upper
limit of the 95 % CI was less than the pre-specified non-
inferiority margin of 8 mm, thus etoricoxib 60 and
90 mg each demonstrated non-inferiority but not super-
iority to naproxen 1000 mg (Table 2).
For the comparison of etoricoxib 90 mg vs. 60 mg, the
time-weighted average change from baseline SPI score
was numerically greater for the etoricoxib 90 mg group
compared to the etoricoxib 60 mg group over 6 weeks of
treatment in Part I, but this difference did not achieve
statistical significance at the pre-specified critical alpha
= 0.20 (p = 0.396). In addition, the observed difference of
1.58 mm of the etoricoxib 90 mg dose over the etori-
coxib 60 mg dose was less than the pre-specified MCID
of 6 mm (Table 2). The time-weighted average response
PGART score was similar between the etoricoxib 60 mg,
etoricoxib 90 mg, and naproxen 1000 mg groups over
6 weeks of treatment in Part I (Table 2).
Additional secondary endpoints in this trial evaluated
treatment effects in Part II of inadequate responders
from Part I. In those subjects who were considered inad-
equate responders to etoricoxib 60 mg in Part I, the
average change from Week 6 over the average of Weeks
10 and 12 in SPI score was statistically significantly bet-
ter (at critical alpha = 0.20) in the group of inadequate
responders who switched to etoricoxib 90 mg (n = 178)
versus the group of inadequate responders who
remained on etoricoxib 60 mg (n = 175) (p = 0.112), al-
though the 2.70 mm difference observed was less than
the prespecified MCID of 6 mm (Fig. 4, Table 3). The
time-weighted average change from baseline SPI score
was similar between the etoricoxib 60 mg/60 mg, etori-
coxib 90 mg/90 mg, and naproxen 1000 mg/1000 mg
groups over 26 weeks of treatment in the study
(Table 3).
The average change from Week 6 over Weeks 10 and
12 in PGART score was similar between the group of in-
adequate responders who remained on etoricoxib 60 mg
and the group of inadequate responders who switched
to etoricoxib 90 mg (nominal p = 0.221) (Table 3). The
etoricoxib 60 mg and etoricoxib 90 mg groups had
slightly higher proportions of subjects who discontinued
due to lack of efficacy compared to the naproxen
1000 mg group; however, the nominal p-values for dif-
ferences were only p = 0.401 and p > 0.999, respectively.
For the measure of time-weighted LS Mean change
from baseline in the BASDAI score, etoricoxib 90 mg
had the greatest change from baseline by the end of Part
I, but the nominal p-value for the 90 mg dose vs. na-
proxen was 0.425; nominal p-value for the 60 mg dose
vs. naproxen was 0.866. Results for the severity and dur-
ation of morning stiffness demonstrated a stronger nu-
merical dose-related trend; however, nominal p-values
for etoricoxib 90 mg vs. naproxen were 0.119 for dur-
ation and 0.131 for severity and for etoricoxib 60 mg vs.
naproxen, nominal p-values were 0.483 for duration and
0.627 for severity (Table 3).
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Safety and tolerability
In Part I, 305 (30 %) subjects experienced an AE with a
similar proportion in each treatment group. The most
common AEs during Part I were upper abdominal pain,
headache, and hypertension (Table 4). In Part II, 282
(31 %) subjects experienced an AE with a similar
proportion of subjects in each treatment group. The
most common AEs during Part II were nasopharyngitis
and headache (Table 5). Among subjects who had
SAEs, there was no dose-dependent trend during Part I.
In Part II, a numerically higher proportion of subjects
on the 90 mg dose or those who escalated to 90 mg
Fig. 1 CONSORT Diagram/Study Design
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from 60 mg had serious AEs compared with subjects
who were on etoricoxib 60 mg throughout the study or
for those in the naproxen group.
With regard to prespecified AEs of interest, which in-
cluded hypertension-related AEs, edema-related AEs,
and AEs of congestive heart failure, pulmonary edema,
or cardiac failure, there were no statistically significant
differences between the treatment groups in either Part I
or Part II; while naproxen had a numerically greater pro-
portion of subjects with hypertension-related AEs, there
were no other dose-dependent trends in the prespecified
AEs of interest.
There were 2 subjects with a total of 3 confirmed/ad-
judicated GI events during the study (1 subject in the
etoricoxib 60 mg/60 mg group and 1 subject [with 2
events] in the etoricoxib 60 mg/90 mg group during Part
II). The events of gastric ulcer and gastric ulcer
hemorrhage experienced by the subject in the etoricoxib
60 mg/90 mg group were confirmed by the adjudication
committee as upper GI bleeds.
There were seven subjects experiencing 8 thrombotic
CV AEs. Two subjects in the etoricoxib 60 mg group in
Part I had an ischemic stroke. In Part II, 2 subjects in
the etoricoxib 60 mg/90 mg group had confirmed
thrombotic CV events (acute myocardial infarction and
sudden death [cause unknown]); 2 subjects had 3 events
in the 90 mg/90 mg group during Part II (one subject
had an ischemic stroke, one subject had a pulmonary
embolism, and one subject had a peripheral venous
thrombosis and pulmonary embolism).
One death occurred in the etoricoxib 60 mg/90 mg
group during the follow-up period after completion of
treatment. The subject was not hospitalized prior to
death, an autopsy was not conducted, and the cause was








N = 702 N = 156 N = 157 N = 1015
n (%) n (%) n (%) n (%)
Gender
Female 209 (29.8) 45 (28.8) 41 (26.1) 295 (29.1)
Male 493 (70.2) 111 (71.2) 116 (73.9) 720 (70.9)
Age (Years)
Mean (SD) 45.4 (12.4) 45.2 (11.3) 44.5 (12.3) 45.2 (12.2)
Range 19–82 19–82 21–75 19–82
Race
White 589 (83.9) 132 (84.6) 138 (87.9) 859 (84.6)
Asian 88 (12.5) 17 (10.9) 16 (10.2) 121 (11.9)
Multi-racial 18 (2.6) 5 (3.2) 3 (1.9) 26 (2.6)
Black 4 (0.6) 2 (1.3) 0 (0.0) 6 (0.6)
Other 3 (0.4) 0 (0.0) 0 (0.0) 3 (0.3)
Chronic Peripheral
Arthritis




177 (25.2) 38 (24.4) 29 (18.5) 244 (24.0)











Spinal Pain Intensity (0–
100 mm VAS)
76.7 (14.2) 76 (15.2) 77.0 (14.0) 76.8 (14.3)
SD standard deviation, VAS visual analog scale
a Radiographic assessment of bilateral sacroiliitis according to the modified NY
criteria for AS
b Responses to BASDAI questions were provided using a 0–100 mm Visual
Analog Scale; the composite BASDAI score was divided by 10 to identify
patients with BASDAI >4
Fig. 2 Spinal Pain Intensity over 26 Weeks
Fig. 3 Time-weighted LS Mean Change from Baseline in Spinal Pain
Intensity (0–100 mm VAS; Primary Endpoint, Part I)
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LS mean difference vs.
naproxen
LS mean difference between 60 mg
and 90 mg; p-Value
Primary Endpoint n = 143 n = 660 n = 144
Time-weighted LS Mean Change from
Baseline in Spinal Pain Intensity





1.59 (−2.19, 5.37) −31.23
(−34.70, −27.76)
−0.64 (−5.47, 4.19) –
Secondary and Tertiary Endpoints n = 154 n = 694 n = 154
Time-weighted LS Mean Change from
Baseline in Spinal Pain Intensity





1.91 (−1.73, 5.55) −30.51
(−33.87, −27.15)
0.33 (−4.33, 4.99) −1.58 (−3.96, 0.81); p = 0.396
Time-weighted Average (LS Mean)
Response over 6 Weeks in PGART (95 % CI)
(mITT population)
2.19 (2.05, 2.32) 2.22 (2.16, 2.29) 0.03 (−0.11, 0.18) 2.29 (2.15, 2.42) 0.10 (−0.09, 0.29) N/A
Proportion of Subjects Who Discontinued
due to Lack of Efficacy (%)
2/154 (1.30) 20/694 (2.88) 1.58 (−0.60, 3.76) 2/154 (1.30) 0.65 (−2.17, 3.47) N/A
Time-weighted LS Mean Change from
Baseline in Bath Ankylosing Spondylitis Disease





−0.25 (−3.15, 2.66) −20.60
(−23.28, −17.92)
−1.51 (−5.23, 2.21) N/A
Time-weighted LS Mean Change from
Baseline in Duration of Morning Stiffness (95 % CI)





1.11 (−4.22, 2.00) −18.29
(−21.16, −15.42)
−3.16 (−7.15, 0.82) −2.05 (−5.17, 1.07)
Time-weighted LS Mean Change from Baseline
in Level of Morning Stiffness over 6 weeks of





−0.85 (−4.27, 2.58) −22.72
(−25.89, −19.56)
−3.38 (−7.76, 1.01) −2.53 (−5.96, 0.91)
Time-weighted LS Mean Change from Baseline
in Spinal Pain Intensity (95%CI) (PP population)
for comparison of etoricoxib 60 mg vs. etoricoxib 90 mg
– – – – – −2.23 (−4.69, 0.23); p = 0.246













determined to be unknown; for these reasons, the adju-
dication committee could not rule out that the subject
had a thrombotic CV event resulting in death.
Discussion
In this study, both etoricoxib 90 and 60 mg were non-
inferior to naproxen 1000 mg on the primary endpoint
of time-weighted average change from baseline in the
SPI score of a 6-week period. These results were further
validated by other endpoints, including PGART and dis-
continuations due to lack of efficacy. An analysis was
done for the secondary objective comparing the effect of
etoricoxib 90 mg vs. etoricoxib 60 mg on the time-
weighted average change from baseline SPI score; the
difference in the effect did not meet the prespecified
MCID. All other secondary and tertiary endpoints sup-
ported similar efficacy between the doses in Part I.
Among the subset of subjects who did not have an ad-
equate response to the 60 mg dose during Part I, those who
received the 90 mg dose in Part II demonstrated an add-
itional average improvement of ~3 mm in SPI score from
Week 6 over Weeks 10 and 12 as compared to subjects
who continued receiving the 60 mg dose in Part II. This re-
sult was identified as being statistically significant in this
study; however, the results were not supported by PGART
results. The 3-mm average improvement with the 90 mg
dose vs. the 60 mg dose also did not meet the predefined
MCID of 6 mm. Further research evaluating MCID on an
individual patient level rather than as an average measure
may be useful in determining if the numerically greater im-
provement from the 90 mg dose provides clinically import-
ant effects for some AS patients. Overall, while etoricoxib
previously demonstrated efficacy in subjects with AS at a
dose of 90 mg [16], our results indicate that etoricoxib
60 mg is a clinically relevant dose that provides efficacy for
a majority of patients similar to that achieved with 90 mg.
An effective lower dose of medication may decrease a pa-
tient’s potential adverse effects, and treatment interruptions.
In the Multinational Etoricoxib and Diclofenac Arthritis
Long-term (MEDAL) study, which was a large outcome
trial that was designed to evaluate safety parameters among
osteoarthritis (OA) and rheumatoid arthritis patients who
received etoricoxib 60 mg, etoricoxib 90 mg, and diclofenac
150 mg, the 60 mg dose (received by OA patients) was as-
sociated with fewer discontinuations due to AEs or serious
AEs compared with OA patients who received etoricoxib
90 mg. Additionally, a lower rate of congestive heart fail-
ure and discontinuations due to edema were observed
with etoricoxib 60 mg vs. etoricoxib 90 mg in the
MEDAL trial [18, 19]. In the current study, all treat-
ments were generally well tolerated with no new or un-
expected safety findings. There were no significant
differences in AEs between treatment groups; however a
small numeric increase in SAEs was noted in Part II in
Fig. 4 Average Change From Week 6 Over Weeks 10 and 12 (Part II)
in Spinal Pain Intensity (0–100 mm VAS)






60 mg (Part I)/
60 mg (Part II)
Etoricoxib
60 mg (Part I)/
90 mg (Part II)
LS mean difference between
etoricoxib 60 mg/90 mg vs.
Etoricoxib 60 mg/60 mg; p-Value
Etoricoxib
90 mg (Part I/
90 mg (Part II)
Number of Subjects n = 74 n = 175 n = 178 n = 70
LS Mean Change from Week 6 in Spinal
Pain Intensity Over Weeks 10 and 12 (95 %











LS Mean Change from Week 6 in PGART
Over Weeks 10 and 12 (95 % CI)
(Inadequate Responders in Part I)
0.21 (0.07, 0.35) 0.13 (0.04, 0.23) 0.21 (0.12, 0.30) 0.08 (−0.05, 0.21) 0.28 (0.13, 0.42)
Number of Subjects n = 141 n = 310 n = 314 n = 140
Time-weighted LS Mean Change from
Baseline in Spinal Pain Intensity Over 26







−1.70 (−5.79, 2.39) −36.76
(−40.22, −33.31)
LS least squares, CI confidence interval, PGART patient global assessment of response to therapy
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90 and 60 mg/90 mg treatment arms as compared to
60 mg treatment arm.
Due to the cardiovascular and gastrointestinal risks as-
sociated with NSAIDs [20], these events were adjudi-
cated by an external committee of experts in this trial.
Further, it should be noted that CV risk is elevated in
AS patients [21]. The proportion of subjects who experi-
enced thrombotic CV or upper GI events was relatively
low and not unexpected in this study. The thrombotic
CV events that occurred in this study were in the etori-
coxib groups with none occurring in the naproxen
group; however, the incidence was too low to ad-
equately assess risk. Previous analyses have suggested
that NSAIDs, including COX-2 selective NSAIDs such
as etoricoxib, have a similar increased risk of CV
events, although with the possible exception of na-
proxen which is not associated with an increased risk
[20]. A large outcome program (the MEDAL program)
demonstrated a similar rate of thrombotic CV events
with etoricoxib (60 or 90 mg) and diclofenac 150 mg;
the MEDAL program also demonstrated a reduced risk
of uncomplicated upper GI events with etoricoxib vs.
diclofenac [22].
This study demonstrated that etoricoxib 60 and 90 mg
are clinically important doses in the treatment of AS
and are non-inferior to naproxen 1000 mg with regard
to reduction of spinal pain intensity. However, the limi-
tation of this study was that assessments of the efficacy
of these doses on an individual patient level were not
studied. Additionally, these treatments were only
assessed based on clinical endpoints. Previous research
demonstrated radiographic improvement in AS patients
treated with NSAIDs, COX-2 selective NSAIDs in par-
ticular, presumably due to inhibition of osteoblast activ-
ity [9]. Though not assessed in this study, the effect of
etoricoxib and other COX2 inhibitors on radiographic










N (%) with AEs 222 (31.6) 36 (23.2) 47 (30.1)
N (%) with AEs determined by the investigator to be drug related 85 (12.1) 11 (7.1) 21 (13.5)
N (%) with serious AEs 5 (0.7) 1 (0.6) 0 (0.0)
N (%) who discontinued due to AEs 22 (3.1) 2 (1.3) 6 (3.8)
Most Common AEs (incidence >2 % in one or more treatment groups)
Upper abdominal pain 19 (2.7) 2 (1.3) 6 (3.8)
Diarrhea 16 (2.3) 2 (1.3) 3 (1.9)
Nasopharyngitis 20 (2.8) 3 (1.9) 1 (0.6)
Dysgeusia 0 (0.0) 4 (2.6) 1 (0.6)
Headache 18 (2.6) 6 (3.9) 2 (1.3)
Hypertension 21 (3.0) 5 (3.2) 6 (3.8)
Serious AEs
Appendicitis 0 (0.0) 1 (0.6) 0 (0.0)
Hip Fracture 1 (0.1) 0 (0.0) 0 (0.0)
Ankylosing Spondylitis 1 (0.1) 0 (0.0) 0 (0.0)
Cerebral Infarction 1 (0.1) 0 (0.0) 0 (0.0)
Cerebrovascular Accident 1 (0.1) 0 (0.0) 0 (0.0)
Headache 1 (0.1) 0 (0.0) 0 (0.0)
Prostatitis 1 (0.1) 0 (0.0) 0 (0.0)
Hypertensive crisis 1 (0.1) 0 (0.0) 0 (0.0)
Prespecified AEs of Interest
Hypertension-related AEs 35 (5.0) 6 (3.9) 6 (3.8)
Discontinuation due to hypertension-related AEs 0 (0.0) 0 (0.0) 0 (0.0)
Edema-related AEs 4 (0.6) 0 (0.0) 0 (0.0)
Discontinuation due to edema-related AEs 0 (0.0) 0 (0.0) 0 (0.0)
Congestive heart failure, pulmonary edema, or cardiac failure 0 (0.0) 0 (0.0) 0 (0.0)
AE adverse event
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N (%) with AEs 97 (31.0) 103 (32.3) 38 (26.2) 44 (31.0)
N (%) with AEs determined by the investigator
to be drug related
20 (6.4) 20 (6.3) 7 (4.8) 12 (8.5)
N (%) with serious AEs 1 (0.3) 7 (2.2) 5 (3.4) 2 (1.4)
N (%) who discontinued due to AEs 3 (1.0) 9 (2.8) 4 (2.8) 2 (1.4)
Serious AEs
Angina Pectoris 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0)
Left ventricular hypertrophy 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0)
Glaucoma 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0)
Gastric Ulcer 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0)
Gastric Ulcer Hemorrhage 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0)
Death 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0)
Non-cardiac Chest Pain 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.7)
Abscess 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.7)
Diverticulitis 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0)
Sialoadenitis 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.7)
Contusion 0 (0.0) 0 (0.0) 1 (0.7) 0 (0.0)
Rib Fracture 0 (0.0) 0 (0.0) 1 (0.7) 0 (0.0)
Skin Abrasion 0 (0.0) 0 (0.0) 1 (0.7) 0 (0.0)
Ankylosing Spondylitis 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0)
Rotator Cuff Syndrome 0 (0.0) 0 (0.0) 1 (0.7) 0 (0.0)
Ear Neoplasm 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0)
Renal Cell Carcinoma 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0)
Ischemic Stroke 0 (0.0) 0 (0.0) 1 (0.7) 0 (0.0)
Depression 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0)
Pulmonary Embolism 0 (0.0) 0 (0.0) 2 (1.4) 0 (0.0)
Deep Vein Thrombosis 0 (0.0) 0 (0.0) 1 (0.7) 0 (0.0)
Hypertension 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0)
Most Common AEs (incidence >2 % in one or more treatment groups)
Upper Abdominal Pain 7 (2.2) 2 (0.6) 0 (0.0) 4 (2.8)
Influenza 1 (0.3) 2 (0.6) 2 (1.4) 3 (2.1)
Nasopharyngitis 9 (2.9) 11 (3.4) 4 (2.8) 3 (2.1)
Urinary tract infection 2 (0.6) 7 (2.2) 0 (0.0) 1 (0.7)
Contusion 2 (0.6) 0 (0.0) 3 (2.1) 3 (2.1)
Arthralgia 8 (2.6) 2 (0.6) 2 (1.4) 0 (0.0)
Headache 6 (1.9) 7 (2.2) 5 (3.4) 4 (2.8)
Hypertension 9 (2.9) 9 (2.8) 3 (2.1) 4 (2.8)
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disease progression in AS patients is a potentially im-
portant area for future research.
Conclusions
In summary, both etoricoxib 90 and 60 mg were well tol-
erated in this study, and no new safety signals were identi-
fied. The sum of the evidence from this study suggests
that etoricoxib 60 and 90 mg effectively control pain and a
choice of two effective doses (60 mg or 90 mg) has now
been described for patients with AS, with 60 mg once
daily as the lowest effective dose for most patients. This
choice of two effective doses provides healthcare providers
with an additional option to optimize AS treatment based
on individual patient response.
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